Evidence map›Paper›PMID 29485986›Full record

SynthesisPLoS medicine2018

Prevalence of sexually transmitted infections and bacterial vaginosis among women in sub-Saharan Africa: An individual participant data meta-analysis of 18 HIV prevention studies.

Elizabeth A Torrone, Charles S Morrison, Pai-Lien Chen, Cynthia Kwok, Suzanna C Francis, Richard J Hayes, Katharine J Looker, Sheena McCormack, Nuala McGrath, Janneke H H M van de Wijgert and 4 more

Erratum issuedOpen access · goldAbstract readMeta-Analysis
In one paragraph

Synthesis in PLoS medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 169 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
169citing papers in PubMed, 10 pooled it
16.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

169 citing papers in PubMed, 10 syntheses or guidelines pooled it, 259 citations in OpenAlex.

  1. Epidemiology ofBMJ global health · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. A systematic review of Neisseria gonorrhoeae drug resistance development in South Africa.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

109 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 9 institutions in 5 countries.

Elizabeth A TorroneDivision of STD Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.ORCID 0000-0002-5154-6332
Charles S MorrisonGlobal Health, Population and Nutrition, FHI 360, Durham, North Carolina, United States of America.
Pai-Lien ChenGlobal Health, Population and Nutrition, FHI 360, Durham, North Carolina, United States of America.
Cynthia KwokGlobal Health, Population and Nutrition, FHI 360, Durham, North Carolina, United States of America.
Suzanna C FrancisTropical Epidemiology Group, London School of Hygiene & Tropical Medicine, London, United Kingdom.ORCID 0000-0002-3724-4813
Richard J HayesTropical Epidemiology Group, London School of Hygiene & Tropical Medicine, London, United Kingdom.ORCID 0000-0002-1729-9892
Katharine J LookerPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.ORCID 0000-0002-3375-0807
Sheena McCormackMRC Clinical Trials Unit, University College London, London, United Kingdom.
Nuala McGrathAcademic Unit of Primary Care and Population Sciences, University of Southampton, Southampton, United Kingdom.
Janneke H H M van de WijgertInstitute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdom.ORCID 0000-0003-2728-4560
Deborah Watson-JonesClinical Research Department, London School of Hygiene & Tropical Medicine, London, United Kingdom.
Nicola LowInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.ORCID 0000-0003-4817-8986
Sami L GottliebDepartment of Reproductive Health and Research, World Health Organization, Geneva, Switzerland.
STIMA Working Group
Family Health International 360 · USLondon School of Hygiene & Tropical Medicine · GBAfrica Health Research Institute · ZACenters for Disease Control and Prevention · USMRC Clinical Trials Unit at UCL · GBUniversity of Bern · CHUniversity of Bristol · GBUniversity of Liverpool · GBWorld Health Organization · CH

Funding

Medical Research Council G0100137Medical Research Council G0701039Medical Research Council G1002369Medical Research Council MC_U122861322Medical Research Council MC_UU_12023/1Medical Research Council MC_UU_12023/23Medical Research Council MR/K012126/1World Health Organization 001
6 · The paper itself

Abstract

backgroundEstimates of sexually transmitted infection (STI) prevalence are essential for efforts to prevent and control STIs. Few large STI prevalence studies exist, especially for low- and middle-income countries (LMICs). Our primary objective was to estimate the prevalence of chlamydia, gonorrhea, trichomoniasis, syphilis, herpes simplex virus type 2 (HSV-2), and bacterial vaginosis (BV) among women in sub-Saharan Africa by age, region, and population type. METHODS AND

findingsWe analyzed individual-level data from 18 HIV prevention studies (cohort studies and randomized controlled trials; conducted during 1993-2011), representing >37,000 women, that tested participants for ≥1 selected STIs or BV at baseline. We used a 2-stage meta-analysis to combine data. After calculating the proportion of participants with each infection and standard error by study, we used a random-effects model to obtain a summary mean prevalence of each infection and 95% confidence interval (CI) across ages, regions, and population types. Despite substantial study heterogeneity for some STIs/populations, several patterns emerged. Across the three primary region/population groups (South Africa community-based, Southern/Eastern Africa community-based, and Eastern Africa higher-risk), prevalence was higher among 15-24-year-old than 25-49-year-old women for all STIs except HSV-2. In general, higher-risk populations had greater prevalence of gonorrhea and syphilis than clinic/community-based populations. For chlamydia, prevalence among 15-24-year-olds was 10.3% (95% CI: 7.4%, 14.1%; I2 = 75.7%) among women specifically recruited from higher-risk settings for HIV in Eastern Africa and was 15.1% (95% CI: 12.7%, 17.8%; I2 = 82.3%) in South African clinic/community-based populations. Among clinic/community-based populations, prevalence was generally greater in South Africa than in Southern/Eastern Africa for most STIs; for gonorrhea, prevalence among 15-24-year-olds was 4.6% (95% CI: 3.3%, 6.4%; I2 = 82.8%) in South Africa and was 1.7% (95% CI: 1.2%, 2.6%; I2 = 55.2%) in Southern/Eastern Africa. Across the three primary region/population groups, HSV-2 and BV prevalence was high among 25-49-year-olds (ranging from 70% to 83% and 33% to 44%, respectively). The main study limitation is that the data are not from random samples of the target populations.

conclusionsCombining data from 18 HIV prevention studies, our findings highlight important features of STI/BV epidemiology among sub-Saharan African women. This methodology can be used where routine STI surveillance is limited and offers a new approach to obtaining critical information on STI and BV prevalence in LMICs.

Indexed as

AdolescentAdultAfrica South of the SaharaFemaleHealth PromotionHIVHIV InfectionsHumansMiddle AgedPrevalenceSexually Transmitted DiseasesVaginosis, BacterialYoung Adult

Identifiers

PMID29485986
PMCPMC5828349
OpenAlexW4294661837

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.